Nothing Special   »   [go: up one dir, main page]

ATE415946T1 - Neue metaxalon-zusammensetzungen - Google Patents

Neue metaxalon-zusammensetzungen

Info

Publication number
ATE415946T1
ATE415946T1 AT04776615T AT04776615T ATE415946T1 AT E415946 T1 ATE415946 T1 AT E415946T1 AT 04776615 T AT04776615 T AT 04776615T AT 04776615 T AT04776615 T AT 04776615T AT E415946 T1 ATE415946 T1 AT E415946T1
Authority
AT
Austria
Prior art keywords
new
metaxalone
metaxalone compositions
compositions
microns
Prior art date
Application number
AT04776615T
Other languages
English (en)
Inventor
John Pruitt
Tuula Ryde
William Bosch
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Application granted granted Critical
Publication of ATE415946T1 publication Critical patent/ATE415946T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT04776615T 2003-08-08 2004-07-26 Neue metaxalon-zusammensetzungen ATE415946T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49344603P 2003-08-08 2003-08-08

Publications (1)

Publication Number Publication Date
ATE415946T1 true ATE415946T1 (de) 2008-12-15

Family

ID=34193183

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04776615T ATE415946T1 (de) 2003-08-08 2004-07-26 Neue metaxalon-zusammensetzungen

Country Status (8)

Country Link
US (1) US20050063913A1 (de)
EP (1) EP1651189B1 (de)
JP (1) JP2007501839A (de)
AT (1) ATE415946T1 (de)
CA (1) CA2534924A1 (de)
DE (1) DE602004018150D1 (de)
ES (1) ES2318330T3 (de)
WO (1) WO2005016310A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29852A (id) * 1998-11-02 2001-10-18 Elan Corp Plc Cs Komposisi pelepasan modifikasi multi partikulasi
US7459283B2 (en) * 2002-02-04 2008-12-02 Elan Pharma International Limited Nanoparticulate compositions having lysozyme as a surface stabilizer
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
WO2004019937A1 (en) * 2002-09-02 2004-03-11 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
ES2760464T3 (es) 2003-04-29 2020-05-14 Nalpropion Pharmaceuticals Inc Composiciones para afectar a la pérdida de peso
EP1755559A1 (de) * 2004-03-08 2007-02-28 Spiridon Spireas Biologisch verfügbare feste dosierformen von metaxalon
US7820817B2 (en) 2004-05-28 2010-10-26 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2006018814A2 (en) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Oral liquid suspensions of metaxalone
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
JP2008530134A (ja) * 2005-02-15 2008-08-07 エラン ファーマ インターナショナル リミテッド ナノ粒子ベンゾジアゼピンのエアロゾル製剤および注射用製剤
EP1855651A4 (de) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen heterocyclischer amidderivate
AU2006235483B2 (en) * 2005-04-12 2010-11-25 Elan Pharma International Limited Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
EA200702444A1 (ru) * 2005-05-10 2008-04-28 Элан Фарма Интернэшнл Лимитед Композиции с наночастицами клопидогреля
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
KR20080047509A (ko) * 2005-05-23 2008-05-29 엘란 파마 인터내셔널 리미티드 혈소판 응집 억제제를 함유하는 나노입자형 조절 방출조성물
US7767710B2 (en) 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
CA2610480A1 (en) * 2005-06-03 2007-05-10 Scott Jenkins Nanoparticulate acetaminophen formulations
WO2006133046A2 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
WO2008073068A1 (en) 2005-06-08 2008-06-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cefditoren
CA2611475A1 (en) * 2005-06-09 2006-12-21 Elan Pharma International, Limited Nanoparticulate ebastine formulations
AU2006259606A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
EP1931340A2 (de) * 2005-06-15 2008-06-18 Elan Pharma International Limited Nanopartikuläre azelnidipin-formulierungen
WO2007010508A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited Controlled release compositions of metaxalone
EP1937217A2 (de) * 2005-09-13 2008-07-02 Elan Pharma International Limited Nanoteilchenförmige tadalafil-formulierungen
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
PL1954241T3 (pl) * 2005-11-28 2013-03-29 Orexigen Therapeutics Inc Formulacja zonisamidu o przedłużonym uwalnianiu
WO2007060682A1 (en) * 2005-11-28 2007-05-31 Strides Arcolab Limited Effervescent granular formulations of antiretroviral drugs
US20070249694A1 (en) * 2005-12-29 2007-10-25 Azaria Caroline A Metaxalone formulations and methods for the preparation thereof
WO2007074477A2 (en) * 2005-12-29 2007-07-05 Dabur Pharma Limited Metaxalone polymorphs
MX2008015275A (es) * 2006-05-30 2009-02-06 Elan Pharma Int Ltd Formulaciones de posaconazol en nanoparticulas.
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2054042B8 (de) 2006-06-30 2020-06-10 iCeutica Pty Ltd Verfahren zur herstellung von biologischen wirkstoffen in nanoteilchenform
US20080213374A1 (en) * 2006-07-10 2008-09-04 Elan Pharma International Limited Nanoparticulate sorafenib formulations
BRPI0714173A2 (pt) * 2006-07-12 2012-12-25 Elan Pharma Int Ltd composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem
KR20180066272A (ko) * 2006-11-09 2018-06-18 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
JP2010509367A (ja) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 積層製剤
US20120093928A1 (en) * 2007-08-09 2012-04-19 Ranbaxy Laboratories Limited Oral metaxalone compositions
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
KR20110007095A (ko) * 2008-03-21 2011-01-21 엘란 파마 인터내셔널 리미티드 이마티니브의 부위-특이적 전달을 위한 조성물 및 사용방법
CA2725930A1 (en) * 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CN104000785B (zh) * 2009-04-24 2021-01-05 伊休蒂卡有限公司 美他沙酮的新剂型
MY159208A (en) 2009-04-24 2016-12-30 Iceutica Pty Ltd A novel formulation of indomethacin
WO2010138539A2 (en) 2009-05-27 2010-12-02 Elan Pharma International Ltd. Reduction of flake-like aggregation in nanoparticulate active agent compositions
US8871793B2 (en) 2009-12-23 2014-10-28 Nuformix Limited Metaxalone cocrystals
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US10500282B2 (en) 2012-12-19 2019-12-10 Kashiv Biosciences, Llc Supersaturated stabilized nanoparticles for poorly soluble drugs
BR112016001395A8 (pt) * 2013-07-22 2020-01-14 Iceutica Inc forma de dosagem unitária oral sólida de metaxalona
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2019217286A1 (en) 2018-05-07 2019-11-14 Prana Biosciences Inc Metaxalone formulations
WO2022102709A1 (ja) * 2020-11-12 2022-05-19 株式会社 メドレックス 粒子を含む組成物が塗布されたマイクロニードルアレイ
CN115300458B (zh) * 2022-08-08 2023-11-07 锦州奥鸿药业有限责任公司 一种无糖地氯雷他定口服溶液及其制备方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993767A (en) * 1975-11-18 1976-11-23 A. H. Robins Company, Incorporated Compositions to suppress gastric bleeding in indomethacin and phenylbutazone therapy
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
EP0179583A1 (de) * 1984-10-04 1986-04-30 Merck & Co. Inc. System zur Verbesserung der Auflösungsgeschwindigkeit in Wasser und der Löslichkeit von schwer löslichen Arzneimitteln
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
JPS62501630A (ja) * 1984-12-26 1987-07-02 サンシヤイン,エイブラハム 鎮痛、抗炎症および骨格筋弛緩薬組成物
US4722938A (en) * 1984-12-26 1988-02-02 Analgesic Associates Methods for using musculoskeletal relaxants
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2112905A1 (en) 1991-07-05 1993-01-21 Michael R. Violante Ultrasmall non-aggregated porous particles entrapping gas-bubbles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
DE4320096C2 (de) * 1993-06-17 1996-03-14 Passavant Werke Biogasreaktor zur anaeroben Behandlung von Abwässern
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル,リミティド ナノ粒子分散体を含有するエアロゾル
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) * 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) * 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) * 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
DE69833000T2 (de) * 1997-09-26 2006-09-07 Noven Pharmaceuticals, Inc., Miami Bio-klebemittelzusammensetzungen
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
JP4156807B2 (ja) * 1999-06-01 2008-09-24 エラン ファーマ インターナショナル,リミティド 小型ミル及びその方法
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6592980B1 (en) * 1999-12-07 2003-07-15 Air Products And Chemicals, Inc. Mesoporous films having reduced dielectric constants
EP1313564B1 (de) * 2000-04-26 2009-12-30 Elan Pharma International Limited Vorrichtung zur sanitären nassvermahlung
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
DE60127355T2 (de) * 2000-08-25 2007-07-05 Honda Giken Kogyo K.K. Hilfsmaschinenaufbau für eine Brennkraftmaschine
PT1392441E (pt) * 2001-06-05 2008-09-30 Elan Pharma Int Ltd Sistema e método para trituração de materiais
DE10153078A1 (de) * 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
ATE385777T1 (de) * 2002-03-20 2008-03-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitoren
US6538142B1 (en) * 2002-04-18 2003-03-25 Farchemia S.R.L. Process for the preparation of metaxalone
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
WO2004019937A1 (en) * 2002-09-02 2004-03-11 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability

Also Published As

Publication number Publication date
CA2534924A1 (en) 2005-02-24
DE602004018150D1 (de) 2009-01-15
EP1651189B1 (de) 2008-12-03
US20050063913A1 (en) 2005-03-24
WO2005016310A1 (en) 2005-02-24
EP1651189A1 (de) 2006-05-03
JP2007501839A (ja) 2007-02-01
ES2318330T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
ATE415946T1 (de) Neue metaxalon-zusammensetzungen
ATE387186T1 (de) Neue zusammensetzungen von sildenafil-freier base
DE60325718D1 (de) Nystatin-nanopartikelzusammensetzungen
WO2005002542A3 (en) Nanoparticulate meloxican formulations
CY1113036T1 (el) Φαρμακοτεχνικες μορφες νανοσωματιδιων μεγεστρολης
SG161203A1 (en) Nanoparticulate tacrolimus formulations
EA200701442A1 (ru) Композиции наночастиц кандесартана
EA200702638A1 (ru) Стабильная композиция (рецептура) с наночастицами ацетаминофена
EA200401556A1 (ru) Препараты на основе наночастиц фибрата
MXPA05007635A (es) Composicion para la limpieza personal que contiene particulas de forma irregular y particulas esfericas.
EA200701107A1 (ru) Твердая фармацевтическая композиция, содержащая валсартан
EA200701997A1 (ru) Композиция из наночастиц бисфосфоната
MY144114A (en) Painting composition having improved rheological characteristics
MX336930B (es) Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
ATE457718T1 (de) Sterile gefilterte nanoteilchen-formulierungen von budesonid mit tyloxapol als oberflächenstabilisator
DE69513183D1 (de) Verdicktes nichtabrasives körperwaschmittel
WO2007002315A3 (en) Nanoparticulate megestrol formulations
DE602006010334D1 (de) Diiodomethyl-p-tolylsulfon als teilchendispersion in einem flüssigen lösungsmittel
BRPI0410417A (pt) composição cermet, e, método para proteger uma superfìcie metálica sujeita à erosão
ATE332120T1 (de) Shampoo mit hohlen teilchen
ATE359765T1 (de) Verringerung der teilchengrösse von bioaktiven verbindungen
PT1453380E (pt) Composicoes contendo sacarido e silica hidrofobica
EP1938803A3 (de) Formulierungen mit Nanoteilchen-Meloxican
TH118234A (th) วัสดุซิลิกาชนิดปิดอุดท่อสำหรับยาสีฟัน

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties